Levosimendan is a calcium sensitizer that demonstrates enhanced myocardial contractility. There is little information concerning the effect of levosimendan on left ventricular tissue parameters and exercise capacity. We evaluated the effects of a 24-h course of levosimendan therapy on cardiac tissue parameters in 30 patients, aged 48 -70 years, admitted to our hospital for the management of decompensated heart failure. All patients underwent echocardiographic examination using tissue Doppler imaging (TDI) and a 6-min walk test. Systolic myocardial velocity of the mitral annulus (Sm) was significantly increased in levosimendantreated patients compared with placebotreated patients. There was a positive correlation between Sm and exercise capacity.
Introduction
Although the therapeutic approach to both severe symptomatic heart failure and asymptomatic cardiac dysfunction has undergone considerable change, important treatment targets still include cardiac remodelling, neuroendocrine and cytokine activation, fluid retention and renal dysfunction. 1 As heart failure is a complex syndrome, the therapeutic approach may require a combination of several strategies targeting different mechanisms. 2, 3 The effectiveness of acute heart failure management depends on rapid diagnosis followed by immediate use of appropriate pharmacological agents to relieve symptoms and reverse the haemodynamic abnormalities. 4 Levosimendan is a calcium sensitizer that also has effects on adenosine triphosphate (ATP)-sensitive potassium channels. As an acute treatment, levosimendan HA Kasikcioglu, S Unal, Z Tartan et al. LV function after levosimendan treatment demonstrates enhanced myocardial contractility with no increase in oxygen demand. In addition, it considerably reduces the incidence of worsening clinical progress in patients with decompensated congestive heart failure. 5 Recently, tissue Doppler imaging (TDI), which measures the velocity of the myocardium during the cardiac cycle, has been used to assess systolic and diastolic function. 6, 7 TDI can be used to calculate both the amplitude and the velocity of mitral annular motion, and it reliably measures changes in cardiac contractility, ejection fraction (EF), ejection time and pressures, and latent left ventricular dysfunction. 6, 7 Although a few standard echocardiographic studies have analysed the left ventricular (LV) systolic and diastolic function in patients with heart failure after levosimendan therapy, no studies have evaluated the relationship between exercise capacity and LV function measured by TDI. We designed this study to evaluate the relationship between TDI-derived measures of long-axis left ventricular function and exercise capacity after levosimendan therapy.
Patients and methods

PATIENTS
Patients, aged 48 -70 years, admitted to our hospital for the clinical management of decompensated heart failure and classified as New York Heart Association (NYHA) functional class III, were enrolled in this randomized, placebo-controlled study. All patients received baseline therapy for heart failure including angiotensin-converting enzyme (ACE) inhibitors and a diuretic, and had left ventricular ejection fractions ≤ 0.35 with hypokinesia of all segments documented within the previous 2 months. Patients were excluded from the study if they had primary valvular heart disease, congenital heart disease, atrial fibrillation/ flutter, unstable angina pectoris, acute or sub-acute myocardial infarction or any other systemic acute or chronic disease.
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the Local Research Ethics Committee. Written informed consent was obtained from all patients before participation.
STUDY DESIGN
Echocardiographic examination and a 6-min walk test were performed at baseline and again after administration of intravenous levosimendan (bolus dose 12 µg/kg for 10 min, followed by a continuous infusion of 0.1 µg/kg per min for 24 h) or placebo after 6 -9 months baseline therapy.
ECHOCARDIOGRAPHIC MEASUREMENTS
Echocardiographic measurements were made at baseline before randomization and again in the first hour after treatment. Echocardiograms were obtained using commercially available ultrasound equipment (GE-VingMed System FiVe with a 3.5 MHz transducer, General Electric-VingMed Sound AB, Horten, Norway). All patients were examined at rest in the left lateral decubitus position. All recordings were performed by an investigator who was blinded to the study information. The echocardiographic techniques and calculations of different cardiac dimensions and volumes were performed according to the recommendations of the American Society of Echocardiography. 8 Left ventricular systolic (LVDs) and diastolic (LVDd) dimensions and EF were measured and calculated in the parasternal long axis with the M-mode cursor positioned just beyond the mitral leaflet tips, HA Kasikcioglu, S Unal, Z Tartan et al. LV function after levosimendan treatment perpendicular to the long axis of the ventricle. Stroke volume (SV) was measured by volumetric method from two orthogonal apical views. 9 A standard apical fourchamber view was recorded first; subsequently, the heart was imaged in an apical long-axis two-chamber view by rotating the transducer. The transducer was carefully angled to clearly maximize the LV size. LV end-diastolic (LVEDV) and end-systolic (LVESV) volumes were measured. 9 The mitral flow velocities were recorded with pulsed-wave Doppler with the sample volume placed at the tip of the mitral valve tips from the apical four-chamber view. The following parameters were measured from the mitral valve inflow velocity curve: peak early-wave velocity (E) and peak late-wave velocity (A). The reproducibility of this method has been described previously. 10 Peak myocardial velocities during systole (Sm), early diastole (Em) and late diastole (Am) were measured with the sample volume placed at the junction of the LV wall and the mitral annulus of the septal and lateral myocardial segments from the fourchamber view (Fig.1 ). The Sm velocity occurs during the ejection period, while the Em and Am velocities correspond to passive ventricular filling and atrial contraction. The reproducibility of this method has been described previously. 10
THE 6-MIN WALK TEST
A 6-min walk test was performed within 12 h of treatment, using a standardized method on a level enclosed corridor 75 m long at baseline. 11 A defibrillator and resuscitation equipment were available throughout the test. All patients were informed of the purpose of the walking test and the details of the method used. Patients were transported to the start of the course by wheelchair, then asked to walk as far as possible within 6 min in order to ensure that the method was standardized and reproducible among patients. They were allowed to set their own walking pace, choosing when to rest and when to stop. During the 6-min walk test, the time was called out after 3 min and 5 min 
STATISTICAL ANALYSIS
Descriptive statistics are presented as mean ± SD. Unpaired t-tests between the levosimendan-and placebo-treated groups were examined at baseline to determine the significance of any initial differences. Differences within the levosimendan-and placebotreated groups from baseline to post-treatment were assessed using a paired t-test, and the significance of any differences between the two groups post-treatment was detected by an independent t-test. The relationship between the haemodynamic measurements and exercise capacity was examined by linear regression analysis. A P-value < 0.05 was considered statistically significant.
Inter-study variabilities were also assessed in randomly selected subjects. Variability was expressed as the mean percentage error, derived as the absolute difference between the two sets of observations, divided by the mean of the observations.
Results
Thirty patients were enrolled in the study and randomized to levosimendan treatment (n = 15) or placebo (n = 15). Baseline characteristics are shown in Table 1 . No significant differences were observed between the two groups in age, height, weight and heart rate at baseline and after treatment.
Although LVDd, LVDs, LVEDV, LVESV and EF were similar when compared between groups at baseline and post-treatment, when comparing within each group before and after treatment, SV in the levosimendantreated group was significantly higher than in the control group post-treatment (P = 0.005) ( Table 1) .
Levosimendan treatment did not change the E wave, A wave, E/A ratio or Am, but significantly increased the Sm and Em velocities compared with placebo treatment in the lateral and septal segments ( Table 2) . Furthermore, levosimendan treatment increased Sm velocity of the lateral segment and the septal segment compared with the placebo-treated group (4.78 ± 0.79 versus 3.81 ± 0.52, P < 0.001; 5.45 ± 0.50 versus 4.01 ± 0.76, P < 0.001, respectively). In addition, the E/Em ratio at the septal segment decreased after levosimendan therapy compared with the placebo-treated group (18.11 ± 5.17 versus 22.79 ± 4.91, P = 0.01).
When the effect of levosimendan on exercise capacity was compared with the placebo-treated group, there was a significant increase in the distance walked following treatment with levosimendan (222 ± 19 m versus 199 ± 16 m, P = 0.001) ( Table 1) . When considering all data, there was a positive correlation between exercise capacity and Sm, in both the septal and lateral segments (r = 0.54, P < 0.01; r = 0.47, P < 0.01, respectively) ( Fig. 2) .
Inter-study variabilities were assessed in 14 randomly selected subjects. The inter-study percentage variability was 2.7% for LVDd, 2.9% for LVDs, 3.7% for LVEDV, 4.3% for LVESV, 3.1% for E wave, 2.9% for A wave, 2.5% for Sm, 2.9% for Em and 2.1% for Am.
Discussion
This study has shown that levosimendan produced consistently favourable effects on systolic function as measured by TDI in patients with heart failure. Previous data have also shown that levosimendan significantly increased cardiac output or cardiac index and decreased filling pressure during the acute treatment of stable or decompensated congestive heart failure. 5, 12 Levosimendan has been shown to improve the proportion of patients achieving
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beneficial haemodynamic responses compared with placebo treatment, with few adverse events. 12 These desirable effects on systolic function were associated with symptom improvement without excess adverse events, raising the possibility that levosimendan might be valuable in the short-term management of patients with decompensated heart failure. 13, 14 Several mechanisms have been proposed for the beneficial actions of levosimendan on LV systolic function. 5, 15, 16 Levosimendan Values are mean ± SD; P 1 value, baseline between-group differences; P 2 value, within-group differences; P 3 value, post-treatment between-group differences; E, early diastolic peak flow velocity; A, late diastolic peak flow velocity; Sm, peak myocardial velocity of systolic wave; Em, peak myocardial velocity of early diastolic wave; Am, peak myocardial velocity of late diastolic wave; NS, not significant. is a calcium sensitizer that works via a dual mechanism of action, providing enhanced contractility via inotropes and decreased pre-or after-load via vasodilators, or altering the process of cardiac remodelling. 5 Levosimendan increases myocardial contractility through calcium sensitization without increasing myocardial oxygen demand and it causes systemic and coronary vasodilatation through activation of ATP-dependent potassium channels in smooth muscle. 5, 15, 16 As a consequence of these actions, it also produces anti-stunning effects without increasing myocardial intracellular calcium concentrations or prolonging myocardial relaxation. 5 In vitro evidence suggests that levosimendan is partly restored by abnormal intracellular calcium haemostasis in myocardial stunning, including decreased myofilament calcium sensitivity. 5 Functional capacity is an important parameter of quality of life and provides prognostic information, 17 but the determinants of exercise capacity and myocardial velocities have not been clearly defined in patients with chronic heart failure. TDI measures of systolic function are related to traditional measures of left ventricular systolic function such as EF. Gulati et al. 7 also reported that Sm is a good measurement of global systolic function and can detect abnormal systolic function in patients with heart failure and a normal EF (diastolic heart failure). 18 TDI might represent a more sensitive method of determining global left ventricular function than traditional indices. 19 With regard to the diastolic parameters measured in this study, increased Em and decreased E/Em were observed after levosimendan treatment. These results Several studies have shown that the early mitral annulus velocity is a relatively pre-load-independent assessment of LV relaxation, 20 and the ratio of peak early diastolic mitral inflow velocity (E) over the myocardial velocity can be used to estimate LV filling pressure. 21 Levosimendan also decreased left filling pressures and systemic arterial pressure. These haemodynamic effects appear to be accompanied by improvements in diastolic function. 14 Changes in myocardial velocities may also support the theory that the increases in coronary flow and the oxygen-sparing effect are secondary to myofilament calcium sensitization. 22 Some authors have suggested that levosimendan might be expected to increase cardiac contractile force without significantly impairing ventricular relaxation and without increasing heart rate due to inotropic and vasodilating properties. 23, 24 Levosimendan increased chamber compliance in late diastole, indicating improved LV filling. 25 This study has demonstrated that myocardial contractile reserve properties are important factors in determining exercise capacity in patients with heart failure, and that levosimendan treatment might increase Sm velocity in parallel with exercise tolerance. The study has also shown that the progress of ventricular function after levosimendan treatment in patients with exercise intolerance can be monitored effectively by TDI.
Conflicts of interest
No conflicts of interest were declared in relation to this article.
